Summer Garey
Family · Chapel Hill, NCNPI 1710630629
Payments from drug & device makers
Across 33 payments — averaging $205.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$4K
- Incyte Corporation$481
- E.r. Squibb & Sons, L.L.C.$343
- Merck$327
- Astellas Pharma US Inc$177
- Jazz Pharmaceuticals Inc.$165
- plus $1K from 10 others
What the payments were for
- Consulting fees$3,99259%
- Food & beverage$2,42636%
- Education$3575%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 4 | $4,218 |
| Incyte Corporation | 9 | $481 |
| E.r. Squibb & Sons, L.L.C. | 3 | $343 |
| Merck | 3 | $327 |
| Astellas Pharma US Inc | 2 | $177 |
| Jazz Pharmaceuticals Inc. | 2 | $165 |
| Servier Pharmaceuticals LLC | 1 | $146 |
| Beigene USA, Inc. | 1 | $129 |
| Syndax Pharmaceuticals, Inc. | 1 | $128 |
| Recordati_rare_diseases_inc. | 1 | $126 |
| Gilead | 1 | $124 |
| Stemline Therapeutics Inc. | 1 | $106 |
| Genentech USA, Inc. | 1 | $97 |
| AbbVie | 1 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $65 |
| Geron Corporation | 1 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,775 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 60 | $652 |
| Potassium Chloride | 43 | $590 |
| Cefdinir | 15 | $445 |
| Levofloxacin | 24 | $304 |
| Pantoprazole Sodium | 28 | $270 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $147 |
| Olanzapine | 11 | $26 |
Paid to pharmacies, not to this prescriber.
Other family in Chapel Hill
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.